Melanoma Agent Surprise: Brain Tumors Shrink TooThe efficacy of dabrafenib evidently extends beyond its targets of solid tumors and melanomas that harbor BRAF mutations, according to findings from a phase 1 trial.
More Patients, More Revenue, but Less Rush. How?Doctors may think the only way to increase revenue is to add services, do more marketing, and change their practice. But there are ways to make more money by adapting what you're already doing. Here's how.
Medscape Business of Medicine, May 2012
Doctors and Marriage: Should You Have a Prenup?Love is powerful, yet marriage always involves some element of risk. Can you protect your finances and your practice in the event of a divorce and still start off a marriage on the right foot?
New AMA Head on Membership, the ACA, and Medicine's FutureDr. James Madara, of the American Medical Association, gives a candid interview on the nation's largest physician organization and whether it has any regrets about supporting the Affordable Care Act.
Medscape Internal Medicine, May 2012
Can a Hospital Say, 'Only Thin Doctors Can Work Here'?A Texas hospital refuses to hire overweight staff, including doctors and nurses. Is this ethical -- or sensible? A leading bioethicist gives his take on the situation.
Colorectal Cancer: New Drugs, Emerging ParadigmsDr. John Marshall highlights colorectal studies on aflibercept, regorafenib, maintenance therapy, perioperative chemotherapy, and second-line therapy, to be presented at ASCO® 2012.
Medscape Hematology-Oncology, May 21, 2012
Plenary Session: 4 Critical Advances in OncologyDr. Kathy Miller previews the ASCO plenary session studies in breast cancer, prostate cancer, lymphoma, and oligodendroglioma, all 4 of which signal significant advances in science and treatment.
